Articles tagged "Rejection"

2020 American Transplant Congress
Single Center Experience in Using Donor-Derived Cell-Free DNA in Kidney Transplant
P. Homkrailas¹, S. Lee², B. Kandagedon¹, G. Danovitch¹, S. Bunnapradist¹
¹Medicine, Division of Nephrology, Kidney and Pancreas Transplant Programs, UCLA, Los Angeles, CA, ²Department of Pharmacy, UCLA, Los Angeles, CA
*Purpose: While the gold standard for diagnosing allograft rejection in kidney transplant recipients (KTX) continues to be histopathologic evaluation, it has been well recognized that…
2020 American Transplant Congress
Follow Up of Imlifidase (IdeS) Desensitized Kidney Transplant Recipients
S. C. Jordan¹, R. A. Montgomery², T. Lundgren³, C. Legendre⁴, N. Desai⁵, G. Eckerwall⁶, L. Laxmyr⁶, H. Olsson⁶, A. Runström⁶, Å. Schiött⁶, K. Sjöholm⁶, E. Sonesson⁶, L. Winstedt⁶, T. Lorant⁷, C. Kjellman⁶
¹Cedars Sinai Medical Center, Los Angeles, CA, ²NYU Langone Health Transplant Institute, New York, NY, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Hospital Necker & Paris Descartes University, Paris, France, ⁵Johns Hopkins University, Baltimore, MD, ⁶Hansa Biopharma AB, Lund, Sweden, ⁷Uppsala University, Uppsala, Sweden
*Purpose: 46 highly sensitized patients received kidney transplants after desensitization with imlifidase (currently under investigation) across four Phase 2 clinical trials, and 6-month safety and…
2020 American Transplant Congress
Reduced Dose of Mycophenolate Mofetil as Well as Preformed DSA Are Risk Factors Associated with the Development of Chronic Active Antibody Mediated Rejection after Kidney Transplantation: A Retrospective Case Control Study
K. Shinoda¹, H. Oguchi¹, K. Nishikawa¹, T. Yonekura¹, M. Muramatsu¹, T. Kawamura¹, Y. Hamasaki¹, T. Mikami², K. Sakai¹, S. Shishido¹
¹Toho University Faculty of Medicine, Tokyo, Japan, ²Pathology, Toho University Faculty of Medicine, Tokyo, Japan
*Purpose: The purpose of this study is to explore the risk factors associated with the development of chronic active antibody mediated rejection (CAAMR) after the…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA May Not Discriminate Rejection in Kidney Transplant Recipients with a Prior Allograft in Place
A. Vo, M. Gillespie, S. C. Jordan, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, E. Huang
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker discriminating rejection in kidney transplant (KTx) patients (pts). However, its performance when stratified by rejection risk…
2020 American Transplant Congress
Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients
H. Sasaki¹, T. Tanabe¹, H. Higuchi¹, T. Tsujimoto², H. Harada¹
¹Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, ²Pharmacy, Sapporo City General Hospital, Sapporo, Japan
*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…
2020 American Transplant Congress
Case Series of Belatacept for Calcineurin Inhibitor Sparing after Lung Transplantation
H. Patel, C. R. Ensor, R. D. Davis, L. Bogar, D. Colella, M. Kildea, J. Kim, A. Satterthwaite, D. Ventura, C. Gries
AdventHealth, Orlando, FL
*Purpose: Belatacept is a recombinant soluble fusion protein which selectively blocks T-cell co-stimulation. It received initial FDA approval for prophylaxis of organ rejection in Epstein-Barr…
2020 American Transplant Congress
Identification of Cell Types That Harbor Cytomegalovirus DNA in Acutely and Latently Infected Mice Spleen
A. S. Maganti¹, X. Liu², M. Abecassis²
¹Illinois Math and Science Academy, Aurora, IL, ²Comprehensive Transplant Center, Northwestern University, Chicago, IL
*Purpose: Cytomegalovirus (CMV) is a ubiquitous β‐herpesvirus that infects majority of humans. Primary CMV infection may be asymptomatic or manifests as a self‐limited febrile illness…
2020 American Transplant Congress
Effect of Simultaneous Presence of Anti-Blood Group A/B and -HLA Antibodies on Clinical Outcomes in Kidney Transplantation Across Positive Crossmatch: A Nationwide Cohort Study
H. Kwon, Y. Ko, D. Han
Department of General Surgery, Asan Medical Center, Seoul, Korea, Republic of
*Purpose: ABO-incompatible (ABOi) and positive crossmatch (XM) kidney transplantation (KT) have been considered immunologically challenging. The present study analyzed the clinical outcomes in XM positive…
2020 American Transplant Congress
Targeting Th17: TIGIT as a Key Regulator of Tregs/Th17 Cells in Belatacept Resistant Rejection
C. R. Hartigan, M. Wagener, M. L. Ford
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Belatacept resistant-rejection (BRR) is a major barrier to the widespread adoption of immune checkpoint blockade therapeutics in transplantation. Our lab has shown that patients…
2020 American Transplant Congress
The Banff Classification of Antibody-Mediated Rejection in Kidney Allografts: Comparison of Predictive Performance for Allograft Failure in Previous and Current Editions
J. Callemeyn¹, H. Ameye¹, M. Coemans¹, A. Senev², E. Lerut³, B. Sprangers¹, D. Kuypers¹, M. Emonds², M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²Histocompatibility and Immunogenetics Laboratory, Red Cross-Flanders, Mechelen, Belgium, ³Imaging and Pathology, KU Leuven, Leuven, Belgium
*Purpose: Since its introduction in 2001, the Banff classification for antibody-mediated rejection (ABMR) has undergone significant changes, mainly by inclusion of C4d-negative ABMR in 2013…